TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* A history typical for recurrent herpes labialis. The subject must have experienced three or more cold sores in the last 12 months.~* In general good health, without other serious medical conditions, as determined by the patient's account of his/her medical history.~* Signature on the informed consent document.~Exclusion Criteria:~* Patients who have participated in an investigational drug study in the four-week period prior to enrollment.~* Previous herpes vaccine at any time.~* Patients with major medical conditions such as chronic heart, pulmonary, renal or hepatic diseases.~* Patients with immunodeficiency disorders such as HIV infection or cancer chemotherapy.~* Patients using topical steroids on or near the face or systemic steroids within 30 days of enrollment.~* Women who are pregnant, lactating or breast feeding.~* Women of childbearing potential not using adequate contraception as judged by the Investigator.~* Recent history of alcohol or drug abuse, which in the opinion of the investigator, may interfere with that study patient's compliance with study requirements.~* Significant skin disease such as atopic dermatitis, acne, or rosacea that would interfere with the assessment of lesions.~* Allergy or hypersensitivity to steroids, acyclovir, penciclovir and/or other nucleoside analogues.~* Subjects with impaired renal function as defined as a serum creatinine above the upper limits of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older;~* Have an atrial arrhythmia with symptoms that has been sustained for greater than 3 hours and up to 45 days.~* Have adequate anticoagulant therapy.~Exclusion Criteria:~* Have a QRS \> 0.14 seconds unless patient has pacemaker or uncorrected QT \> 0.440 seconds as measured on a 12-lead ECG.~* Have serious diseases/illnesses that could interfere with the conduct or validity of the study or compromise patient safety.~* Have received intravenous Class I or Class III antiarrhythmic drugs or intravenous amiodarone within 24 hours prior to dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Atrial fibrillation (AF) duration of 3 hours to 7 days.
- 2 (Type: EXPERIMENTAL): AF duration of \>7 days to \<45 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Centered Medication Adherence Intervention for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medical chart diagnosis of schizophrenia or schizoaffective disorder;~* currently prescribed outpatient antipsychotic medication (oral or depot);~* patient must have adequate capacity to provide informed consent, understand the nature of the study, and sign an informed consent document.~Exclusion Criteria:~- significant cognitive impairment as indicated by a score \> 10 on the Blessed Orientation-Memory-Concentration (BOMC) Test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
- Antipsychotic adherence intervention (Type: EXPERIMENTAL): Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or more who had previously untreated microinvasive SCC, providing they satisfied both of the following conditions:~  * tumor invasion into the papillary dermis (Clark level II) according to a biopsy specimen and~ * difficulty in surgical excision because of health problems (bleeding tendency or cardiac problems)~Exclusion Criteria:~* pregnancy or lactation~* active systemic infectious disease~* other inflammatory, infectious, or neoplastic skin diseases in the treated area~* allergy to MAL,other topical photosensitizers, or excipients of the cream~* history of photosensitivity~* use of immunosuppressive or photosensitizing drugs~* participation in any other investigational study in the preceding 30 days~* history or indicators of poor compliance~* Histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- AFL-PDT (Type: EXPERIMENTAL): Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
- MAL-PDT (Type: ACTIVE_COMPARATOR): Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with a singleton pregnancy that are admitted for induction or augmentation of labor.~2. Women at gestational age 370/7 or more.~3. Vertex presentation.~Exclusion Criteria:~1. Age under 18 or over 45.~2. High order gestation.~3. Women with contraindication for vaginal delivery.~4. Active labor.~5. Women with a uterine scar.~6. Multiparity(\> 5 deliveries).~7. Documented fetal anomalies.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Intermittent treatment (Type: ACTIVE_COMPARATOR): Infusion of oxytocin for 6 hours at a time until patient delivers.
- Continous treatment (Type: ACTIVE_COMPARATOR): Infusion of oxytocin continuously from patient admission for 16 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RSHF in Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> or = 18 years~* Social Insurance~* Performance Index \<2~* Life expectancy\> 6 months~* adenocarcinoma colorectal (histologically proven)~* Metastases (inoperable or recurrent after surgery),~* hepatic localization and / or lung (up to 3 if one organ metastasis or 3 in total if the two bodies are metastatic). The largest diameter of the metastasis will \< ou = 6cm for the liver, \< or = 6 cm for the lung. If multiple metastases, the sum of their maximum diameter is 6cm \< ou = the liver, \< ou = 6 cm for the lung.~* Lesion (s) measurable (s) and evaluable (s)~* CT less than 3 weeks~* Patients must have received at least one prior chemotherapy regimen containing 5FU~  • Patients may have received one or more lines of chemotherapy including irinotecan.~* bilirubin \<1.5 x ULN~* AST and ALT \<5x ULN~* neutrophils\> 1.5x109 / L, platelets\> 100x109 / L, hemoglobin\> 9 g / dL~* TP, TCA Normal (only for patients treated with a permanent implant)~* Informed consent signed.~Exclusion Criteria:~* contraindication to the administration of irinotecan.~* History of radiotherapy in the thoraco-abdominal-cons indicating further irradiation.~* History of other invasive cancer treated in a period of less than 5 years (basal cell carcinoma and non-invasive cervical excepted)~* Metastatic disease diffuse or more than three metastases in the liver and / or lung during the natural history of disease (excluding any patient is having a complete radiological response on several metastases although 1-3 residual after treatment ( s) medical (at)).~* Location (s) tumor (s) = CTV to less than 12 mm laterally or less than 15 mm in the cranio-caudal, stomach, small intestine, esophagus, trachea, bronchi of right and left pulmonary arteries and right and left.~* Pregnancy or breastfeeding.~  - Lack of means or refusal to use effective contraception for men or women of childbearing age.~* Any other concomitant experimental treatment.~* Any other concurrent anticancer therapy, immunotherapy or hormonal therapy.~* Monitoring impossible because of psychological, sociological or because of geographical distance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation + Irinotecan (Type: OTHER): Irinotecan will be administered :~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy~Radiotherapy (RSHF) will be administered :~* at D1, D3, D8 and D10~* 48 Gy, 12 Gy by fractions twice a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years old~* Subject must have histological diagnosis of epithelial ovarian cancer~* Subject must have received a taxane and platinum regimen and have maintained a treatment-free status for at least six months and not more than twelve months following completion of first line therapy.~* Subject must have measurable ovarian cancer by appropriate radiological imaging.~* ECOG performance Score of 0 or 1.~* Subject's life expectancy must be \> 6 months.~* Subject must have normal organ function, except if abnormal due to tumor involvement:~  * Adequate bone marrow function (platelets \>=100 X 10\^9/L, hemoglobin \>=100 g/L, neutrophils \>=1.5 X 10\^9/L)~ * Adequate renal function (serum creatinine\<=1.5 X the upper limit of normal (ULN)~ * Adequate liver function (bilirubin and AST or ALT\<=2 times ULN, unless related to primary disease.~* MUGA scan must indicate left ventricular ejection fraction above 90%.~* Women of childbearing potential must be using adequate contraception (prescribed under medical supervision) and have a negative pregnancy test at the time of enrollment.~* Subject must be able to sign written informed consent.~Exclusion Criteria:~* Subject who is pregnant or is breast feeding.~* Subject who has history of cardiac disease, with New York Heart Association Class II or greater.~* Subject with a history of severe hypersensitivity reactions to products containing Cremophor® EL.~* Subject with clinically significant hepatic disease.~* Subject who has uncontrolled bacterial, viral, or fungal infection.~* Subject who exhibits confusion or disorientation.~* Subject with any condition that would prevent adequate follow-up.~* Subject with a history of prior malignancy treated with systemic chemotherapy or radiotherapy.~* Subject who has received two or more prior chemotherapy regimens for ovarian cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* routine ovulation induction protocol with GnRH agonist~* less than three prior IVF cycles~* at least three aspirated oocytes~* BMI \<35 kg/m2~* age \<45 years~Exclusion Criteria:~* history of dysfunctional uterine bleeding~* acute urogenital disease~* recurrent miscarriage~* previous allergic reactions to a progesterone products

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Oral dydrogesterone (Type: ACTIVE_COMPARATOR): Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
- Crinone 8% vaginal gel (Type: ACTIVE_COMPARATOR): Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women and males of the same body mass index and ethnicity~Exclusion Criteria:~Patients with:~* other inflammatory disorders,~* hepatic disease~* renal disease~* malignant disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type-2 diabetes being treated with oral or parenteral hypoglycemic therapy or both.~* Have not had thienopyridine therapy for at least 30 days before the study.~* Are of legal age (at least 18 years of age but less than 75 years of age) and competent mental condition to provide written informed consent.~* For women of child-bearing potential only test negative for pregnancy at the time of enrollment.~Exclusion Criteria:~* Have a defined need for thienopyridine therapy.~* Subjects within ≤30 days of coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).~* Known glycosylated hemoglobin (HbA1c) ≥10 mg/dL within last 3 months prior to study entry.~* Have received fibrinolytic therapy \<48 hours prior to randomization.~* Have active internal bleeding or history of bleeding diathesis.~* Have clinical findings that are, in the judgment of the investigator, associated with an increased risk of bleeding.~* Have history of ischemic or hemorrhagic stroke, transient ischemic attack (TIA) or intracranial neoplasm, arteriovenous malformation, or aneurysm.~* Have an International Normalized Ratio (INR) known to be \>1.5 within 1 week of study entry.~* Have a known platelet count of \<100,000/mm3 within 1 week of study entry.~* Have known anemia (hemoglobin \[Hgb\] \<10 gm/dL) within 1 week of study entry.~* Are receiving or will receive oral anticoagulation or other antiplatelet therapy (other than ASA) that cannot be safely discontinued for the duration of the trial.~* Are receiving daily treatment with non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be discontinued.~* Have a concomitant medical illness that in the opinion of the investigator may interfere with or prevent completion in this study.~* Have known severe hepatic dysfunction (e.g., cirrhosis or portal hypertension).~* Have a history of intolerance or allergy to ASA or approved thienopyridines (ticlopidine or clopidogrel).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor + Aspirin (Type: EXPERIMENTAL): Loading-dose plus daily-dosing for 5-7 days.
- Clopidogrel + Aspirin (Type: ACTIVE_COMPARATOR): Loading-dose plus daily-dosing for 5-7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Crow-Fukase syndrome (confirmed by diagnostic criteria.)~2. Recurrent or refractory Crow-Fukase syndrome.~3. Patients without severe liver or renal dysfunction.~4. Patients without severe neutropenia or thrombocytopenia.~5. Patients without clinically problematic ECG findings~6. Negative on the pregnacy test on the day 1 of cycle 1.~7. Patients who can undertake prevention of pregnancy, if necessary.~8. Patients with written informed consent.~9. Patients who are capable of ambulatory hospital visits every 4 weeks.~10. Patients with informed consent to the registration and rules of RevMate®.~Exclusion Criteria:~1. Patients who have been administered, bortezomib, lenalidomide, melpharan within 4 weeks prior to the registration.~2. Patients who have been on steroid treatment (more than 10mg/day in predonine) within 2 weeks prior to the registration.~3. Patients who have been administered bevacizumab within 12 weeks prior to the registration.~4. Patients who could worsen acutely during the clinical trial period.~5. Patients with severe complicaitons ( cardiac failure, renal failure liver failure, bleeding enterogastric ulcer, ileus, poorly controlled diabetes.~6. Patients with malignancies.~7. Female patients who are pregnant or desire childbearing. Males who desire fertility.~8. Patients who allergic to lenalidomide or dexamethasone.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide+Dexamethasone (Type: EXPERIMENTAL): Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with the following subtypes of inherited EB: junctional EB (JEB), dystrophic EB (DEB), and Kindler EB aged ≥21 days~* Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days and \<9 months)~* Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed consent~* Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions~Exclusion Criteria:~* Patient has EB simplex~* EB target wound that is ≥9 months old or has clinical signs of local infection~* Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment~* Administration of systemic or topical steroids (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures \[e.g., Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL\]) within 30 days before enrolment~* Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment~* Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB~* Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas~* Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry~* Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes~* Pregnant or nursing women and women of childbearing potential including postmenarchal female adolescents not willing to use an effective form of birth control with failure rates \<1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomised partner) during participation in the study (and at least 3 months thereafter)~* Patient is a member of the investigational team or his/her immediate family~* Patient lives in the same household as a study participant

- Gender: ALL
- Minimum Age: 21 Days
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oleogel-S10 (Type: EXPERIMENTAL): None
- Control Gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete